Long-term ticagrelor cuts risk of future events after heart attack

Adding the antiplatelet drug ticagrelor to aspirin as long-term therapy after a heart attack significantly reduced the rate of subsequent death from cardiovascular causes, heart attack or stroke, with the benefit appearing to accrue for nearly three years, according to a new study.



from Today's Healthcare News -- ScienceDaily http://ift.tt/1GUHQXx